In a phase II study of 165 patients who experienced painful DPN for 1 to 5 years and had a pain score of 40 mm on the Short-Form McGill Pain Questionnaire visual analogue scale (VAS), the daily pain score at the study end point was significantly lower in patients treated with gabapentin than in those treated with placebo for 8 weeks
To reduce error, pretreatment values were the mean of measurements on days 2, 1 and 0, and final values were the mean of days 18, 19 and 20
Certain peptides like BPC-157 and Sermorelin have shown strong benefits in these areas and we have seen the results firsthand at our clinic
Indication context: Semaglutide injection is FDA-approved under brand names Ozempic (type 2 diabetes, CV risk reduction) and Wegovy (chronic weight management, obesity or overweight with 1 weight-related comorbidity)
Managers shouldn't call these shots alone
What they found: Mean weight loss: 2.6 kg vs 2.3 kg placebo , a difference of only 0.3 kg (1 %) Statistically non-significant Clinically unsatisfactory for the obesity indication Safety profile remained favorable Why it matters: The study stopped the development of AOD-9604 as a drug